

해외 바이오의약품 임상 현황 ('22년 11월 2주)

한국바이오의약품협회, 2022.11.15.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
 NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.
 - 출처: ClinicalTrials.gov
 - 모니터링 기간: 2022.11.07. ~ 2022.11.13.
 - 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05582096	A Study of LY3457263 in Obese Participants	Drug: LY3457263 Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05582096
NCT05579977	Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity	Drug: PF-07081532 Other: Placebo Drug: Rybelsus	Pfizer	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05579977
NCT05462990	A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA	Drug: QUC398 Drug: Placebo	Novartis Pharmaceuticals Novartis	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05462990
NCT05518487	COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study	Biological: Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID) PPD Johns Hopkins University Sanofi Pasteur, a Sanofi Company	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05518487
NCT05060003	Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection	Drug: Atezolizumab Drug: Tiragolumab Device: Signatera Assay	Washington University School of Medicine Genentech, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05060003
NCT05575492	A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age	Biological: mRNA-1647 Other: Placebo	ModernaTX, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05575492
NCT05613088	A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Drug: MORAb-202 Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin (PLD) Drug: Topotecan	Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05613088
NCT05174221	A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Drug: Mezagitamab	Takeda	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05174221

○ 영국 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05575492	A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age	Biological: mRNA-1647 Other: Placebo	ModernaTX, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05575492
NCT05174221	A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Drug: Mezagitamab	Takeda	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05174221

○ 중국 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05499390	AK112 in Advanced Non-Small Cell Lung Cancer	Drug: AK112 Drug: Pembrolizumab	Akeso	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05499390
NCT05174221	A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Drug: Mezagitamab	Takeda	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05174221

해외 바이오의약품 임상 현황 ('22년 11월 2주)

한국바이오의약품협회, 2022.11.15.

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05613088	A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Drug: MORAb-202 Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin (PLD) Drug: Topotecan	Bristol-Myers Squibb	Phase 2	
NCT05174221	A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Drug: Mezagitamab	Takeda	Phase 1	